
    
      This study will enroll adults with type 2 diabetes mellitus and elevated LDL-C or
      non-high-density lipoprotein cholesterol (non-HDL-C) levels on a stable, maximally tolerated
      statin dose of at least moderate-intensity at signing of the informed consent; statin therapy
      must remain unchanged during screening and the remainder of the study.
    
  